journal article·2009-02Open access

Platelet and endothelial adhesion on fluorosurfactant polymers designed for vascular graft modification

Chad Tang, Faina Kligman, Coby C. Larsen, Kandice Kottke‐Marchant, Roger E. Marchant

Abstract

Abstract A prominent failure mechanism of small diameter expanded polytetrafluoroethylene (ePTFE) vascular grafts is platelet‐mediated thrombosis. We have designed a surface modification for ePTFE consisting of a self‐assembling fluorosurfactant polymer (FSP) bearing biologically active ligands, including adhesive peptides and polysaccharide moieties. The goal of this biomimetic construct is to improve graft hemocompatibility by promoting rapid surface endothelialization, whereas minimizing platelet adhesion. Here we present a direct comparison of platelet and endothelial cell (EC) adhesion to FSPs containing one of three cell‐adhesion peptides: cyclic Arg‐Gly‐Asp‐D‐Phe‐Glu (cRGD), cyclic *Cys‐Arg‐Arg‐Glu‐Thr‐Ala‐Trp‐Ala‐Cys* (cRRE, *denotes disulfide bond cyclization), linear Gly‐Arg‐Gly‐Asp‐Ser‐Pro‐Ala (RGD), or a polysaccharide moiety: oligomaltose (M‐7), later designed to prevent nonspecific protein adhesion. Measurements of soluble peptide‐integrin binding indicated that cRRE exhibits very low affinity for the αIIbβ3 platelet fibrinogen receptor. Static and dynamic adhesion of washed, activated platelets on FSP‐modified surfaces revealed that M‐7 and cRRE promote significantly less platelet adhesion compared to RGD and cRGD FSPs, whereas EC adhesion was similar on all peptide FSPs and minimal on M‐7 FSP. These results illustrate the potential for ligands presented in a FSP surface modification to selectively adhere ECs with limited platelet attachment. © 2008 Wiley Periodicals, Inc. J Biomed Mater Res 2009
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Polymer Surface Interaction Studies · Electrospun Nanofibers in Biomedical Applications · Protease and Inhibitor Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (49)

Show source-provided references
1. 10.1046/j.1525-1594.2002.06841.x10.1046/j.1525-1594.2002.06841.x ↗
2. 10.1002/jbm.b.3024710.1002/jbm.b.30247 ↗
3. George JN · 2001
4. 10.1016/S1054-8807(02)00183-710.1016/S1054-8807(02)00183-7 ↗
5. 10.1096/fsb2fasebj.12.1.4310.1096/fsb2fasebj.12.1.43 ↗
6. Glycocalyx‐mimetic dextran‐modified poly(vinyl amine) surfactant coating reduces platelet adhesion on medical‐grade polycarbonate surface10.1016/j.biomaterials.2006.01.002 ↗
7. 10.1002/1097-4636(200108)56:2<159::AID-JBM1080>3.0.CO;2-R10.1002/1097-4636(200108)56:2<159::AID-JBM1080>3.0.CO;2-R ↗
8. 10.2174/092986704336460310.2174/0929867043364603 ↗
9. Sporn LA · 2001 · 615
10. Kottke‐Marchant K · 2006 · 491
11. 10.1038/nbt1101-102910.1038/nbt1101-1029 ↗
12. 10.1016/S0142-9612(03)00343-010.1016/S0142-9612(03)00343-0 ↗
13. 10.1076/apab.106.2.100.438410.1076/apab.106.2.100.4384 ↗
14. 10.1016/j.biomaterials.2006.05.00910.1016/j.biomaterials.2006.05.009 ↗
15. 10.1021/ma030423w10.1021/ma030423w ↗
16. 10.1038/3539310.1038/35393 ↗
17. 10.1016/S1473-0502(03)00044-210.1016/S1473-0502(03)00044-2 ↗
18. 10.1080/1521654050007896210.1080/15216540500078962 ↗
19. 10.1080/1541906021414810.1080/15419060214148 ↗
20. 10.1096/fasebj.8.12.752219410.1096/fasebj.8.12.7522194 ↗
21. 10.1146/annurev.cellbio.12.1.69710.1146/annurev.cellbio.12.1.697 ↗
22. 10.1021/ja960372110.1021/ja9603721 ↗
23. 10.1083/jcb.124.3.37310.1083/jcb.124.3.373 ↗
24. 10.1006/abio.1996.045110.1006/abio.1996.0451 ↗
25. 10.1016/j.biomaterials.2007.04.02610.1016/j.biomaterials.2007.04.026 ↗
26. 10.1021/ma00103a01110.1021/ma00103a011 ↗
27. 10.1002/1439-7633(20000818)1:2<107::AID-CBIC107>3.0.CO;2-410.1002/1439-7633(20000818)1:2<107::AID-CBIC107>3.0.CO;2-4 ↗
28. 10.1016/j.biomaterials.2004.07.01010.1016/j.biomaterials.2004.07.010 ↗
29. 10.1002/cyto.99010041310.1002/cyto.990100413 ↗
30. 10.1021/ma970740110.1021/ma9707401 ↗
31. 10.1006/scel.1995.004010.1006/scel.1995.0040 ↗
32. Selective recognition of cyclic RGD peptides of NMR defined conformation by αIIb β3, αVβ3, and α5β1 integrins10.1016/S0021-9258(17)31981-6 ↗
33. 10.1126/science.106904010.1126/science.1069040 ↗
34. 10.1074/jbc.M10586820010.1074/jbc.M105868200 ↗
35. 10.1161/01.ATV.18.9.136310.1161/01.ATV.18.9.1363 ↗
36. 10.1074/jbc.M00056820010.1074/jbc.M000568200 ↗
37. 10.1159/00008384510.1159/000083845 ↗
38. 10.1083/jcb.86.3.79510.1083/jcb.86.3.795 ↗
39. 10.1111/j.1742-4658.2006.05500.x10.1111/j.1742-4658.2006.05500.x ↗
40. 10.1002/jbm.1015110.1002/jbm.10151 ↗
41. 10.1002/(SICI)1097-4636(19980905)41:3<377::AID-JBM6>3.0.CO;2-910.1002/(SICI)1097-4636(19980905)41:3<377::AID-JBM6>3.0.CO;2-9 ↗
42. 10.1002/jbm.a.1013010.1002/jbm.a.10130 ↗
43. 10.1016/S0006-3495(96)79484-510.1016/S0006-3495(96)79484-5 ↗
44. Adult human endothelial cell seeding using expanded polytetrafluoroethylene vascular grafts: A comparison of four substrates
45. 10.1016/j.biomaterials.2007.02.00610.1016/j.biomaterials.2007.02.006 ↗
46. 10.1021/bm050611p10.1021/bm050611p ↗
47. Padera R · 2004
48. 10.1016/S0142-9612(03)00478-210.1016/S0142-9612(03)00478-2 ↗
49. 10.1056/NEJMoa04381410.1056/NEJMoa043814 ↗